- SSRI/SNRI treatment is consistently associated with reduced abundance of Clostridium sensu stricto 1.
- This reduction is specific to SSRI/SNRI treatment and not observed with other psychotropic medications.
- SSRI/SNRI status explains Clostridium reductions between MDD patients and controls, indicating medication effects should be accounted for in microbiome research.
Commun Med (Lond). 2026 Jul 16;6(1):399. doi: 10.1038/s43856-026-01782-5.
ABSTRACT
BACKGROUND: The gut microbiome has been linked to major depressive disorder (MDD), yet it remains unclear whether antidepressant treatment influences these associations. This study aimed to clarify the role of serotonin reuptake inhibitors (SSRI/SNRI) in shaping gut microbiome changes observed in MDD.
METHODS: We conducted cross-sectional analyses in two independent patient cohorts (total N = 1802) and a meta-analysis across both cohorts, comparing the gut microbiome of MDD patients with and without SSRI/SNRI treatment.
RESULTS: Here we show that SSRI/SNRI treatment is consistently associated with reduced Clostridium sensu stricto 1 abundance. This effect is specific to SSRI/SNRI treatment and not observed with other psychotropic medications. Importantly, reductions in Clostridium sensu stricto 1 in MDD compared to unaffected controls are explained by SSRI/SNRI medication status.
CONCLUSIONS: Antidepressant treatment is an important factor shaping gut microbiome alterations linked to MDD, underscoring the need to account for medication effects and potentially informing future microbiome-based strategies to improve treatment response.
PMID:42463908 | DOI:10.1038/s43856-026-01782-5
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

